Agoracom: Small Cap Investment - Resverlogix Corp. - Re: Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer Study

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer Study

lightmyfire2

Sep 24, 2021 09:35AM

Re: Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer Study

golfyeti

Sep 24, 2021 10:03AM

Re: Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer Study

fuzzyjr

Sep 24, 2021 10:19AM

Carman2

Rank: Treasurer [?]

Points: 572 [?]

Votes: 11 Score: 3.1 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer Study

in response to

Re: Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer Study

fuzzyjr

posted on Sep 26, 2021 05:07PM

What study are they refering to where the Zenith drug had a poor showing?
" ... Furthermore, patients in that trial that had a poor response to prior abiraterone therapy had the most durable response with ZEN-3694 + enzalutamide..... ."

1 Recommendations

Reply New Message

Back To Forum List View

Please to post a reply